MAT
51
-4
AKAM
47
5
MU
42
-4
FITB
68
3
MMC
61
-3
CHD
50
2
LRCX
49
-3
IR
77
6
AIV
61
3
MTCH
40
14
SLB
57
4
TGNA
62
-2
EMN
55
5
SCHW
64
8
AMP
76
3
JCI
63
2
AMAT
49
-3
LNC
50
5
COF
68
3
WAT
61
-3
MAT
51
-4
AKAM
47
5
MU
42
-4
FITB
68
3
MMC
61
-3
CHD
50
2
LRCX
49
-3
IR
77
6
AIV
61
3
MTCH
40
14
SLB
57
4
TGNA
62
-2
EMN
55
5
SCHW
64
8
AMP
76
3
JCI
63
2
AMAT
49
-3
LNC
50
5
COF
68
3
WAT
61
-3
Financhill
Back

Pacira BioSciences 10K Form

Sell
39

PCRX
Pacira BioSciences

Last Price:
16.81
Seasonality Move:
14.03%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive PCRX News And Ratings

See the #1 stock for the next 7 days that we like better than PCRX

PCRX Financial Statistics

Sales & Book Value

Annual Sales: $674.98M
Cash Flow: $49.83M
Price / Cash Flow: 4.92
Annual Sales: $16.24
Price / Book: 1.08

Profitability

EPS (TTM): -2.01000
Net Income (TTM): $-90.73M
Gross Margin: $490.31M
Return on Equity: -10.74%
Return on Assets: -5.77%

Pacira BioSciences Earnings Forecast

Key Pacira BioSciences Financial Ratios

  • The Gross Profit Margin over the past 16 years for PCRX is 72.64%.
  • The Selling, General & Administrative Expenses for PCRX have been equal to 39.92% of Gross Profit Margin.
  • The Research & Development expenses have been 11.30% of Revenue.
  • The Interest Expense is 41.26% of Operating Income.
  • The Net Earning history of PCRX is 6.22% of Total Revenues.
  • Per Share Earnings over the last 16 years have been positive in 8 years.

Pacira BioSciences Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: PCRX
CUSIP: 695127
Website: pacira.com

Debt

Debt-to-Equity Ratio: 0.78
Current Ratio: 2.25
Quick Ratio: 1.81

Price-to-Earnings

Trailing P/E Ratio: 19.65
Forward P/E Ratio: 6.2

PCRX Technical Analysis vs Fundamental Analysis

Sell
39
Pacira BioSciences (PCRX) is a Sell

Is Pacira BioSciences a Buy or a Sell?